The Federal Trade Commission announces it will hold a workshop to explore competition issues involving biologic medicines and follow-on biologics. As described in the Federal Register Notice, the workshop will focus on a few key issues, inter alia:
- The potential impact of state regulations affecting competition.
- How regulations, if necessary, might be structured to facilitate competition while still protecting patient health and safety.
- How naming may affect competition.
- The experience of other countries with follow-on biologic competition.
The Federal Register Notice poses a series of questions about which the FTC seeks public comment. The FTC will take these comments into account in its examination of these topics.